The Effect of Colchicine on Platelet Function Profiles in Patients With Stable Coronary Artery Disease

Phase 1

Recruiting

• Conditions: Coronary Artery Disease
• Interventions: Drug: Colchicine 0.5 MG oral tablet twice daily

• Registration Number: NCT06567678
• Lead Sponsor: The University of The West Indies

Brief Summary

The effects of colchicine on cardiovascular health in patients with stable coronary artery disease have been shown to be beneficial due to its anti-inflammatory properties. This present study aims to explore the effects of colchicine on platelet reactivty in patients with coronary artery disease on dual antiplatelet therapy.

Detailed Description

Recent landmark clinical trials on the use of colchicine in patients with chronic coronary artery disease has led to its implementation as an FDA approved drug for secondary prevention in patients with coronary artery disease. Colchicine exerts a range of anti inflammatory effects which plays a major role in reduction of atherosclerosis and prevention cardiovascular events. This current study aims to investigate the effect of colchicine on platelet reactivity in patients with stable coronary artery disease already on dual anticoagulants.

Study Timeline

• Status Verified: 2024-08
• Study First Submitted: 2024-08-20
• Study First Submitted QC: 2024-08-20
• Last Update Submitted: 2024-08-20
• Study Start: 2024-08-21
• Study First Posted: 2024-08-23
• Last Update Posted: 2024-08-23
• Primary Completion: 2025-07-20
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Patients with stable coronary artery disease 2. Patients older than 18 years of age. 3. Patients currently on dual anti platelets, aspirin and clopidogrel

Exclusion Criteria

• 1. Patients already on colchicine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Colchicine 0.5mg po bd	Colchicine 0.5 MG oral tablet twice daily	Patients with coronary disease taking Colchicine 0.5mg twice-daily orally for two weeks

Primary Outcome Measures

Name	Time	Method
P2Y12 reaction units and Aspirin reaction units	two weeks	P2Y12 and Aspirin reaction units pre and post colchicine 0.5mg twice daily oral dose.

Trial Locations

Locations (1)

The University of The West Indies; 🇹🇹 Saint Augustine, Trinidad and Tobago